ICLR — ICON Public Limited Company stock price, charts and financials

QT62ICON Public Limited Company

ICON Public Limited Company (NASDAQ: ICLR) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
165.40
+0.89+0.54%
OverviewShort InterestFilings
ICLRQT62ICON Public Limited Company·NASDAQ
165.40+0.54%
TA
Loading chart...
Signal & projected range
QT Score upgradeHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
CRL+0.85%$269.76RVTY+1.06%$115.87MEDP+1.01%$596.66QGEN+4.72%$44.30TWST+7.30%$124.11GH+0.50%$169.32LH-0.02%$319.11DGX-0.44%$237.29
Snapshot
Index-P/E38.34EPS (ttm)4.29Insider Own0.02%Shs Outstand76.57MPerf Week0.57%
Market Cap12.60BForward P/E13.80EPS next Y11.92Insider Trans0.00%Shs Float75.85MPerf Month-2.52%
Enterprise Value15.16BPEG-EPS next Q2.70Inst Own-Short Float3.42%Perf Quarter31.61%
Income327.50MP/S1.53EPS this Y148.77%Inst Trans-Short Ratio2.21Perf Half Y13.15%
Sales8.25BP/B1.35EPS next Y12.48%ROA2.01%Short Interest2.60MPerf YTD-9.72%
Book/sh-P/C7.80EPS next 5Y12.81%ROE3.54%52W High205.01 -19.32%Perf Year5.85%
Cash/sh-P/FCF9.36EPS past 3/5Y-22.08% -14.21%ROIC4.80%52W Low66.93 147.12%Perf 3Y-34.59%
Dividend Est.-EV/EBITDA12.18Sales past 3/5Y2.15% 24.15%Gross Margin21.85%Volatility4.41% 4.19%Perf 5Y-32.38%
Dividend TTM-EV/Sales1.84EPS Y/Y TTM-55.30%Oper. Margin10.15%ATR (14)8.14Perf 10Y109.06%
Dividend Ex-Date-Quick Ratio0.95Sales Y/Y TTM-0.35%Profit Margin3.99%RSI (14)50.73Recom2.50
Dividend Gr. 3/5Y-Current Ratio0.95EPS Q/Q-19.75%SMA20-1.58%Beta1.18Target Price164.75
Payout0.00%Debt/Eq0.37Sales Q/Q2.28%SMA503.18%Rel Volume0.38Prev Close164.51
Employees40,350LT Debt/Eq0.33EarningsOct 28SMA20011.46%Avg Volume989.86KPrice165.40
IPO DateMay 15, 1998Option/ShortYes / YesEPS/Sales Surpr.0.57% 2.95%Net Debt/EBITDA2.06Volume371,173Change0.54%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-31-26ReiteratedRobert W. Baird$192 → $194
Jun-30-26UpgradeTruist SecuritiesHold → Buy$159 → $207
Jun-26-26ReiteratedMizuhoOutperform$216 → $190
Jun-25-26ReiteratedRobert W. Baird$168 → $186
Jun-25-26ReiteratedBarclaysEqual Weight$200 → $175
Jun-25-26ReiteratedBMO CapitalOutperform$100 → $187
Jun-25-26UpgradeRBC CapitalSector Perform → Outperform$126 → $185
Jun-24-26ReiteratedUBSBuy$150 → $160
Jun-24-26ReiteratedBarclaysEqual Weight$200 → $175
Jun-01-26ReiteratedD.A. DavidsonOutperform$164
Latest News
Aug-06-26
Aug-06-2612:31PM
Is ICON a Buy as Valuation Improves but Earnings Risks Still Persist?zacks.com
06:30AM
ICON Announces Pricing of USD 2.15 Billion Notesbusinesswire.com
Aug-05-26
Aug-05-2612:01PM
ICLR Jumps 33.2% in Three Months as Recovery Expectations Strengthenzacks.com
Aug-04-26
Aug-04-2608:39AM
ICON Announces Private Offering of Notesbusinesswire.com
Aug-01-26
Aug-01-2604:05AM
Icon Plc $ICLR Shares Sold by Avidity Partners Management LPdefenseworld.net
Jul-31-26
Jul-31-2604:15PM
ICON Announces Results of Annual General Meetingbusinesswire.com
04:13PM
Citigroup Maintains Neutral on Icon, Raises Price Target to $180Benzinga
Jul-30-26
Jul-30-2606:43PM
ICON Public Limited Company (ICLR) Q2 2026 Earnings Call Transcriptseekingalpha.com
01:08PM
Icon Q2 Earnings Call Highlightsmarketbeat.com
Jul-29-26
Jul-29-2609:36PM
Icon PLC (ICLR) Lags Q2 Earnings Estimateszacks.com
04:15PM
ICON Reports Second Quarter 2026 Resultsbusinesswire.com
Jul-28-26
Jul-28-2607:00AM
ICON announces multi-year collaboration with Anthropic to bring frontier AI to clinical trialsbusinesswire.com
Jul-27-26
Jul-27-2608:26AM
GreensKeeper Value Fund Q2 2026 Portfolio UpdateSeekingAlpha
Jul-23-26
Jul-23-2612:30PM
Icon PLC (ICLR) Up 5.8% Since Last Earnings Report: Can It Continue?zacks.com
Jul-22-26
Jul-22-2606:00AM
ICON Schedules Second Quarter 2026 Earnings Conference Callbusinesswire.com
Company

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue8,2538,2518,282——————
Cost of Goods Sold Incl. D&A6,4506,0765,845——————
Gross Profit1,8042,1762,436——————
Selling, General and Administrative Excl. Other772780728——————
Research and Development
000——————
Other Operating Expense193383611——————
Operating Income8381,0121,098——————
Interest Expense187188237——————
Unusual Expense
—————————
Non-Operating Income (Expense)-233-5729——————
Net Income Before Taxes418252869——————
Income Taxes902378——————
Consolidated Net Income329229791——————
Net Income From Continuing Operations329229791——————
Net Income329229791——————
EPS (Recurring)4.292.929.60——————
EPS (Basic, Before Extraordinaries)4.292.929.60——————
EPS (Diluted)4.262.909.53——————
EBITDA1,2458241,564——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio38.8362.8322.01——————
Price To Sales Ratio1.541.722.08——————
Gross Margin21.8626.3729.41——————
Operating Margin10.1512.2713.26——————
Net Margin3.992.789.55——————
Shares Outstanding777882——————
Market Capitalization12,73614,21317,196——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$221.35$181.42$141.50$101.58$61.65● Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.